KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to $38.5 million.

  • Xenon Pharmaceuticals' Cash from Investing Activities rose 763714.86% to $38.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $253.8 million, marking a year-over-year increase of 24645.95%. This contributed to the annual value of $165.0 million for FY2024, which is 24813.48% up from last year.
  • As of Q3 2025, Xenon Pharmaceuticals' Cash from Investing Activities stood at $38.5 million, which was up 763714.86% from $82.3 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' 5-year Cash from Investing Activities high stood at $109.2 million for Q2 2024, and its period low was -$239.8 million during Q4 2023.
  • In the last 5 years, Xenon Pharmaceuticals' Cash from Investing Activities had a median value of $8.2 million in 2021 and averaged -$17.4 million.
  • As far as peak fluctuations go, Xenon Pharmaceuticals' Cash from Investing Activities tumbled by 194302.63% in 2023, and later soared by 763714.86% in 2025.
  • Xenon Pharmaceuticals' Cash from Investing Activities (Quarter) stood at -$215.4 million in 2021, then soared by 94.55% to -$11.7 million in 2022, then crashed by 1943.03% to -$239.8 million in 2023, then soared by 141.08% to $98.5 million in 2024, then plummeted by 60.88% to $38.5 million in 2025.
  • Its last three reported values are $38.5 million in Q3 2025, $82.3 million for Q2 2025, and $34.5 million during Q1 2025.